BioTheryX is a clinical-stage biopharmaceutical company focused on degrading proteins to create life-saving cancer medicines.
BioTheryX focuses on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with cancer and other diseases.
BioTheryX was founded in 2008 by David Stirling and Lawrence Zaslow. The company is headquartered in San Diego, California.
BioTheryX's principal technology platform centers on targeted protein degradation with our PHM® ‘molecular glues’, that enable the design of small molecules to regulate protein equilibrium.
BioTheryX's technology is designed to utilize the body's own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability for a broad range of diseases, including targets that have to date been considered 'undruggable.
BioTheryX is backed by Farallon Capital Management, MSD Partners, Avidity Partners, Deep Track Capital, Janus Henderson Investors, Point72, Rock Springs Capital and others. The company raised $92M in Series E round on May 20, 2021. This brings BioTheryX's total funding to $128.7M to date.